Skip to main content

Table 3 Medication changes at patient level

From: Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice

  Δ1 (baseline to 6-month follow-up) Δ2 (6-month follow-up to 9-month follow-up)
Intervention group (IG)
(n = 252)
Control group (CG)
(n = 250)
Total (N = 502) Proportion difference
IG vs. CG
(95% CI)
Intervention group (IG)
(n = 252)
Control group (CG)
(n = 250)
Total (N = 502) Proportion difference
IG vs. CG
(95% CI)
API
 Addition 160 (63%) 153 (61%) 313 (62%) 0.02
(−0.07;0.11)
P = 0.661
93 (37%) 88 (35%) 181 (36%) 0.02
(− 0.07;0.11)
P = 0.761
 Discontinuation 176 (70%) 161 (64%) 337 (67%) 0.05
(− 0.03;0.14)
P = 0.229
119 (47%) 129 (52%) 248 (49%) −0.04
(− 0.14;0.05)
P = 0.373
 Intraclass substitution 23 (9%) 18 (7%) 41 (8.2%) 0.02
(− 0.03;0.07)
P = 0.532
14 (6%) 7 (3%) 21 (4%) 0.03
(− 0.01;0.07), P = 0.187
 Restart of previously discontinued drugs n.a. 51/176
(29%)
53/161
(30%)
104/337
(31%)
− 0.01
(− 0.08;0.07), P = 0.876
Strength of the API
 Increase 46 (18%) 36 (14%) 82 (16%) 0.04
(− 0.03;0.11)
P = 0.295
45 (18%) 35 (14%) 80 (16%) 0.04
(−0.03;0.11), P = 0.29
 Decrease 44 (17%) 49 (20%) 93 (19%) −0.02
(− 0.09;0.05), P = 0.616
31 (12%) 37 (15%) 70 (14%) − 0.02
(− 0.09;0.04), P = 0.492
Dosage
 Daily dosage increase 91 (36%) 80 (32%) 171 (34%) 0.04
(− 0.05;0.13), P = 0.38
67 (27%) 61 (24%) 128 (26%) 0.02
(−0.06;0.1), P = 0.646
 Daily dosage decrease 106 (42%) 79 (32%) 185 (37%) 0.1 (0.02;0.19), P = 0.019* 72 (29%) 58 (23%) 130 (26%) 0.05
(− 0.03;0.13), P = 0.203
 Application interval shortened 55 (22%) 42 (17%) 97 (19%) 0.05
(− 0.02;0.12), P = 0.189
32 (13%) 20 (8%) 52 (10%) 0.05
(− 0.01;0.1), P = 0.114
 Application interval prolonged 48 (19%) 35 (14%) 83 (17%) 0.05
(− 0.02;0.12), P = 0.161
28 (11%) 26 (10%) 54 (11%) 0.01
(−0.05;0.07), P = 0.91
 Change in application time point 145 (58%) 155 (62%) 300 (60%) − 0.04
(− 0.13;0.05), P = 0.353
98 (39%) 118 (47%) 216 (45%) − 0.08
(− 0.17;0.01), P = 0.073
 Pill splitting started 43 (17%) 35 (14%) 78 (16%) 0.03
(−0.04;0.1), P = 0.41
23 (9%) 19 (8%) 42 (8%) 0.02
(− 0.04;0.07), P = 0.648
 Pill splitting stopped 30 (12%) 35 (14%) 65 (13%) −0.02
(− 0.08;0.04), P = 0.571
13 (5%) 18 (7%) 31 (6%) − 0.02
(− 0.07;0.03), P = 0.445
Administration method
 Change in administration method 47 (19%) 32 (13%) 79 (16%) 0.06
(− 0.01;0.13), P = 0.093
37 (15%) 42 (17%) 79 (16%) −0.02
(− 0.09;0.05), P = 0.597
  1. API active pharmaceutical ingredient
  2. *Difference between intervention group and control group was statistically significant